Neutrophil gelatinase-associated lipocalin as a potential therapeutic integrator of glycolipid metabolic and inflammatory signaling

Junhua Gong; Rongtao Zhu; Jianping Gong; Kun He; Jiahai Chen

doi:10.18203/2349-2902.isj20173376

Authors

Junhua Gong Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
Rongtao Zhu Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
Jianping Gong Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
Kun He Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China
Jiahai Chen Department of Surgery, Zhongxian County, Chongqing, 404300, China

DOI:

https://doi.org/10.18203/2349-2902.isj20173376

Keywords:

Glycolipid metabolic dysfunction, Inflammation, Metabolic disease, Neutrophil gelatinase-associated lipocalin

Abstract

Metabolic syndrome constitutes a group of metabolic conditions that increase the risk of developing diseases, including cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), obesity and type 2 diabetes mellitus (T2DM) etc. Subclinical inflammation is a candidate etiological factor in the pathogenesis of metabolic syndrome and in the progression of related diseases. Although studies have revealed that subclinical inflammation was activated by intermediary products of basic metabolic processes, the cellular and molecular mechanisms in this association remain largely uncharacterized. Recently, increasing evidence suggests that neutrophil gelatinase-associated lipocalin (NGAL) not only plays a significant role in the glycolipid metabolism, but also modulates immune and inflammatory responses in macrophages. Taking together the ability of NGAL in metabolic and inflammatory signaling, these data suggest that NGAL may be a potential therapeutic target for metabolic and inflammatory signaling for intervention in human glycolipid metabolic disease. This review focuses on current knowledge of the integrators role of NGAL in both glucose and lipid metabolism and inflammatory signaling and discusses the potential therapeutic target in the treatment of glycolipid metabolic-related disease.

Metrics

Metrics Loading ...

References

McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34(12):2637-43.

Kodama K, Toda K, Morinaga S, Yamada S, Butte AJ. Anti-CD44 antibody treatment lowers hyperglycaemia and improves insulin resistance, adipose inflammation, and hepatic steatosis in diet-induced obese mice. Diabetes. 2015;64(3):867-75.

Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab. 2014;20(4):614-25.

Qian W, Zhu T, Tang B, Yu S, Hu H, Sun W, et al. Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J Clin Endocrinol Metab. 2014;99(12):4683-9.

Wang M, Zhang Q, Zhao X, Dong G, Li C. Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the ED: an observational study. Crit Care. 2014;18(6):634.

Akerstrom B, Flower DR, Salier JP. Lipocalins: unity in diversity. Biochim Biophys Acta. 2000;1482:1-8.

Xu MJ, Feng D, Wu H, Wang H, Chan Y, Kolls J, et al. The liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: A critical role for IL-6/STAT3. Hepatol. 2015;61(2):692-702.

Lee S, Park JY, Lee WH, Kim H, Park HC, Mori K, et al. Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J Neurosci. 2009;29(1):234-49.

Ferreira MC, Whibley N, Mamo AJ, Siebenlist U, Chan YR, Gaffen SL. Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis. Infect Immun. 2014;82(3):1030-5.

Marti J, Fuster J, Hotter G, Sola AM, Deulofeu R, Modolo MM, et al. Serum neutrophil gelatinase-associated lipocalin in patients with colorectal liver metastases: preliminary results of an exploratory prospective study. Int J Biol Markers. 2010;25(1):21-6.

Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycaemia in humans. Clin Chem. 2007;53:34-41.

Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-35.

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.

Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-6.

Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterol. 2007;132(6):2169-80.

Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2276-83.

Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333-6.

Zhao L, Chen Y, Varghese Z, Huang A, Tang R, Jia B, et al. Murine gamma herpes virus 68 infection promotes fatty liver formation and hepatic insulin resistance in C57BL/6J mice. Hepatol Int. 2012;6:520-30.

Mei M, Zhao L, Li Q, Chen Y, Huang A, Varghese Z, et al. Inflammatory stress exacerbates ectopic lipid deposition in C57BL/6J mice. Lipids Health Disease. 2011;10:110.

Libby P, Ridker PM, Hansson GK. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-19.

Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol. 2008;22:1416-26.

Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycaemia in humans. Clin Chem. 2007;53:34-41.

Huang Y, Yang Z, Ye Z, Li Q, Wen J, Tao X, et al. Lipocalin-2, glucose metabolism and chronic low-grade systemic inflammation in Chinese people. Cardiovasc Diabetol. 2012;11:11.

Cakal E, Ozkaya M, Engin-Ustun Y, Ustun Y. Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. J Endocrinol Invest. 2011;34(2):97-100.

Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56(10):2533-40.

Guo H, Jin D, Zhang Y, Wright W, Bazuine M, Brockman DA, et al. Lipocalin 2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes. 2010;59;1376-85.

Jin D, Guo H, Young Bu S, Zhang Y, Hannaford J, Douglas G., et al. Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure. FASEB J. 2011;25:754-64.

Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1β a proteomic analysis. Biotechnol Bioeng. 2005;91:502-15.

Jung M, Sola A, Hughes J, Kluth DC, Vinuesa E, Vinas JL, et al. Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. Kidney Int. 2012;81:969-82.

Hamzic N, Blomqvist A, Nilsberth C. Immune-induced expression of lipocalin-2 in brain endothelial cells: relationship to interleukin-6, cyclooxygenase-2 and the febrile response. J Neuroendocrinol. 2013;25(3):271-80.

Borkham-Kamphorst E, Drews F, Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int. 2011;31(5):656-65.

Fujino RS, Tanaka K, Morimatsu M, Tamura K, Kogo H, Hara T. Spermatogonial cell-mediated activation of an IkappaBzeta-independent NF-kappa B pathway in Sertoli cells induces transcription of the lipocalin-2 gene. Mol Endocrinol. 2006;4:904-15.

Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kB. Am J Pathol. 2006;169:2245-53.

Karlsen JR, Borregaard N, Cowland JB. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. J Biol Chem. 2010;285(19):14088-100.

Glaros T, Fu Y, Xing J, Li L. Molecular mechanism underlying persistent induction of LCN2 by lipopolysaccharide in kidney fibroblasts. PloS One. 2012;7(4):e34633.

Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax. 2012;67:533-9.

Sultan S, Pascucci M, Ahmad S, Malik IA, Bianchi A, Ramadori P, et al. Lipocalin-2 is a major acute phase protein in a rat and mouse model of sterile abscess. Shock. 2012;37(2);191-6.

Guglani L, Gopal R, Rangel-Moreno J, Junecko BF, Lin Y, Berger T, et al. Lipocalin 2 regulates inflammation during pulmonary Mycobacterial infections. PLoS ONE 2012; 7(11): e50052.

Labbus K, Henning M, Borkham-Kamphorst E, Geisler C, Berger T, Mak TW, et al. Proteomic profiling in Lipocalin 2 deficient mice under normal and inflammatory conditions. J Proteomics. 2013;78:188-96.

Sunil VR, Patel KJ, Nilsen-Hamilton M, Heck DE, Laskin JD, Laskin DL. Acute endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in lung and liver. Experimental Molecular Pathol. 2007;83:177-87.

Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L. Red Eagle A, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116-20.

Shashidharamurthy R, Machiah D, Aitken JD, Putty K, Srinivasan G, Chassaing B, et al. Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice. Arthritis Rheum. 2013;65(4):1064-73.

Sola A, Weigert A, Jung M, Vinuesa E, Brecht K, Weis N, et al. Sphingosine-1-phosphate signalling induces the production of Lcn-2 by macrophages to promote kidney regeneration. J Pathol. 2011;225(4):597-608.

Yoo do Y, Ko SH, Jung J, Kim YJ, Kim JS, Kim JM. Bacteroides fragilis enterotoxin upregulates lipocalin-2 expression in intestinal epithelial cells. Lab Invest. 2013;93(4):384-96.

Dittrich AM, Krokowski M, Meyer HA, Quarcoo D, Avagyan A, Ahrens B, et al. Lipocalin2 protects against airway inflammation and hyperresponsiveness in a murine model of allergic airway disease. Clin Exp Allergy. 2010;40(11):1689-700.

Naude PJ, Nyakas C, Eiden LE, Ait-Ali D, Van Der Heide R, Engelborghs S, et al. Lipocalin 2: Novel component of proinflammatory signalling in Alzheimer’s disease. FASEB J. 2012;26:2811-23.

Zhang J, Wu Y, Zhang Y, LeRoith D, Bernlohr DA, Chen X. The Role of Lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Molecu Endocrinol. 2008;22:1416-26.